These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 19065700)

  • 41. [TNF-alpha inhibitors].
    Fain O
    Rev Prat; 2003 Nov; 53(18):1989-90. PubMed ID: 15008210
    [No Abstract]   [Full Text] [Related]  

  • 42. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
    Guillevin L; Mouthon L
    J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
    [No Abstract]   [Full Text] [Related]  

  • 43. Mechanisms of action of tumor necrosis factor antagonist and granulomatous infections.
    Beenhouwer D; Wallis R; Broder M; Furst DE
    J Rheumatol; 2004 Oct; 31(10):1888-92. PubMed ID: 15487038
    [No Abstract]   [Full Text] [Related]  

  • 44. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
    Bombardieri S; Ferraccioli G; Ferri C; Galeazzi M; Lapadula G; Cerinic MM; Montecucco C; Triolo G; Trotta F; Valentini G
    Reumatismo; 2009; 61 Suppl 1():1-23. PubMed ID: 19999184
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Pharmacotherapy of rheumatoid arthritis in the era of genetically engineered biological preparations].
    Nasonov EL
    Ter Arkh; 2007; 79(5):5-8. PubMed ID: 17672066
    [No Abstract]   [Full Text] [Related]  

  • 46. Anti-tumor necrosis factor-alpha agents for rheumatoid arthritis: assessing longterm safety.
    Hyrich KL; Silman AJ
    J Rheumatol; 2006 May; 33(5):831-3. PubMed ID: 16652412
    [No Abstract]   [Full Text] [Related]  

  • 47. Systemic listeriosis with adalimumab therapy.
    Murphy G; Schmidt-Martin D; Hynes BG; Harney S
    J Clin Rheumatol; 2009 Oct; 15(7):369-70. PubMed ID: 20009978
    [No Abstract]   [Full Text] [Related]  

  • 48. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
    Lurati A; Pontikaki I; Teruzzi B; Desiati F; Gerloni V; Gattinara M; Cimaz R; Fantini F
    Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
    Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
    Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Taiwan experience with etanercept in juvenile rheumatoid arthritis.
    Lai JH
    J Microbiol Immunol Infect; 2005 Dec; 38(6):451-4. PubMed ID: 16341348
    [No Abstract]   [Full Text] [Related]  

  • 51. Mycobacterium chelonae infection associated with adalimumab therapy.
    Díaz F; Urkijo JC; Mendoza F; de la Viuda JM; Blanco M; Unzurrunzaga A; Ayarza R
    Scand J Rheumatol; 2008; 37(2):159-60. PubMed ID: 18415777
    [No Abstract]   [Full Text] [Related]  

  • 52. Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis.
    Fleischmann R; Shealy D
    Mol Interv; 2003 Sep; 3(6):310-8. PubMed ID: 14993463
    [No Abstract]   [Full Text] [Related]  

  • 53. Antibodies against mutated citrullinated vimentin fail to predict anti-TNFalpha treatment response in rheumatoid arthritis.
    Dejaco C; Duftner C; Klotz W; Schirmer M; Herold M
    Scand J Rheumatol; 2009; 38(1):66-7. PubMed ID: 18759163
    [No Abstract]   [Full Text] [Related]  

  • 54. Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register.
    Anink J; Otten MH; Prince FH; Hoppenreijs EP; Wulffraat NM; Swart JF; ten Cate R; van Rossum MA; van den Berg JM; Dolman KM; Koopman-Keemink Y; Armbrust W; Kamphuis S; van Pelt PA; Gorter SL; van Suijlekom-Smit LW
    Rheumatology (Oxford); 2013 Apr; 52(4):712-7. PubMed ID: 23267169
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-tumour necrosis factor-alpha treatment of juvenile idiopathic arthritis in a patient with common variable immunodeficiency.
    Kilic SS
    J Trop Pediatr; 2005 Jun; 51(3):194-5. PubMed ID: 15855303
    [No Abstract]   [Full Text] [Related]  

  • 56. Rituximab therapy produced rapid and sustained clinical improvement in a patient with systemic onset juvenile idiopathic arthritis refractory to TNF alpha antagonists.
    Feito JG; Pereda CA
    J Clin Rheumatol; 2009 Oct; 15(7):363-5. PubMed ID: 20009975
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Introduction to biological drugs].
    Fernández-Cruz E; Alecsandru D; Rodríguez-Sainz C
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():2-6. PubMed ID: 19080985
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-TNF-alpha therapies: they are all the same (aren't they?).
    Mpofu S; Fatima F; Moots RJ
    Rheumatology (Oxford); 2005 Mar; 44(3):271-3. PubMed ID: 15561736
    [No Abstract]   [Full Text] [Related]  

  • 59. TNF blocker drugs used to fight inflammation go head-to-head. Adalimumab had highest treatment response and remission rates, etanercept has longest drug survival rates; infliximab placed third.
    Duke Med Health News; 2010 Mar; 16(3):3. PubMed ID: 20461880
    [No Abstract]   [Full Text] [Related]  

  • 60. Adalimumab-associated multiple sclerosis.
    Bensouda-Grimaldi L; Mulleman D; Valat JP; Autret-Leca E
    J Rheumatol; 2007 Jan; 34(1):239-40; discussion 240. PubMed ID: 17216704
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.